Ponia Violeta - Company finances
|
EUR
|
2023
From: 2023-03-23
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|
|
Financial data
|
|||
| Sales revenue | 27,912 | 37,229 | 51,155 |
| Profit before tax | 7,792 | -5,340 | 8,661 |
| Net profit | 7,792 | -5,340 | 8,430 |
| Equity | 7,793 | 2,453 | 10,884 |
| Liabilities | 261 | 111 | 465 |
| Non-current assets | 1,624 | 1,150 | 675 |
| Current assets | 6,430 | 1,414 | 10,674 |
| Total assets | 8,054 | 2,564 | 11,349 |
|
Financial indicators
|
|||
| Revenue change y/y | - | +33.4% | +37.4% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 96.7% | -208.3% | 74.3% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 100.0% | -217.7% | 77.5% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 27.9% | -14.3% | 16.5% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 27.9% | -14.3% | 16.9% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.0 | 0.0 | 0.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Ponia Violeta - Social security debts
The company had no debts to Sodra
Ponia Violeta - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-03-20 | 2026-06-02 | 0.04 |
| 2026-03-08 | 2026-03-11 | 0.04 |
| 2026-03-02 | 2026-03-07 | 48.57 |
| 2026-02-14 | 2026-03-01 | 46.0 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Ponia Violeta, MB (code 306280124) is a Lithuanian small partnership engaged in retail sale of pharmaceutical products. In the latest financial year, 2025, the company generated revenue of €51.2K and net profit of €8.4K, which corresponds to a profit margin of 16.5%. The 2025 result marks a clear recovery after 2024, when revenue increased to €37.2K but the company recorded a net loss of €5.3K. In 2023, revenue was €27.9K and net profit €7.8K, showing that the business has grown over the three-year period despite a temporary setback in 2024. Over the 2023–2025 period, revenue increased by 83.3% in total, supported by a 37.4% year-on-year rise in 2025. The balance sheet at the end of 2025 remained very solid, with total assets of €11.3K, equity of €10.9K and liabilities of €465. The equity ratio stood at 95.9%, debt-to-equity at 0.04, asset turnover at 4.51x, ROE at 77.5% and ROA at 74.3%.